Fact checked byShenaz Bagha

Read more

February 06, 2023
1 min read
Save

Karuna to license Goldfinch Bio's psych, neuro treatment candidates

Fact checked byShenaz Bagha
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Biopharmaceutical company Karuna Therapeutics has announced an exclusive license agreement with biotech firm Goldfinch Bio for its investigational transient receptor potential canonical 4 and 5 channel candidates, including GFB-887.

Karuna plans to assess the transient receptor potential canonical 4 and 5 (TRPC4/5) candidates as potential treatment options for various psychiatric and neurological conditions. GFB-887 will be the first evaluated for treating mood and anxiety disorders.

Corporate looking handshake_Adobe
Karuna Therapeutics and Goldfinch Bio agreed to partner on potential psychiatric and neurological therapies. Image: Adobe Stock

“We are incredibly excited to expand and diversify our development efforts and are encouraged about the potential of TRPC4/5 inhibitors to treat both mood and anxiety disorders based on pre-clinical and clinical data demonstrating anxiolytic and antidepressant properties of these inhibitors,” Steve Paul, MD, president of research and development and chief scientific officer of Karuna, said in a press release. “Our lead candidate in the TRPC4/5 program, GFB-887, has already demonstrated a compelling safety profile in non-clinical and clinical studies.”

Under the agreement, the Goldfinch Bio estate will be eligible to receive up to

$520 million in milestone payments for each licensed TRPC4/5 candidate.